

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 24. (canceled)

25. (currently amended) A method for treating a solid tumor comprising administering ~~a substance an anti-human CXCR4 antibody or a fragment thereof that inhibits binding of SDF-1 to human CXCR4, to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is an anti-human CXCR4 antibody or a fragment thereof that binds to human CXCR4 inhibits growth of, or reduces the size of, the solid tumor.~~

26. (currently amended) A method for treating a disease pathologically caused by neovascularization comprising administering ~~a substance an anti-human CXCR4 antibody or a fragment thereof that inhibits binding of SDF-1 to human CXCR4, to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is an anti-human CXCR4 antibody or a fragment thereof that binds to human CXCR4 inhibits neovascularization.~~

27. (canceled)

28. (currently amended) A method for suppressing vascularization comprising administering ~~a substance an anti-human CXCR4 antibody or a fragment thereof that inhibits binding of SDF-1 to human CXCR4, to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is an anti-human CXCR4 antibody or a fragment thereof that binds to human CXCR4 inhibits vascularization.~~

29-36. (canceled)

37. (new) The method of claim 25, wherein the anti-human CXCR4 antibody or fragment thereof binds to the region of human CXCR4 which interacts with SDF-1.

38. (new) The method of claim 26, wherein the anti-human CXCR4 antibody or fragment thereof binds to the region of human CXCR4 which interacts with SDF-1.

39. (new) The method of claim 28, wherein the anti-human CXCR4 antibody or fragment thereof binds to the region of human CXCR4 which interacts with SDF-1.